Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21381606 | 0.85 | MAPK1 (0.37) | CDK2CTSAS1PR3GRM5SRC | |
| SCHEMBL8218238 | 0.79 | CDK2 (0.35) | CDK2CTSAS1PR3HCAR2GRM5 | |
| SCHEMBL26122997 | 0.78 | MAPK1 (0.39) | CDK2CTSAS1PR3GRM5SRC | |
| SCHEMBL30556962 | 0.78 | MAPK1 (0.39) | CDK2CTSAS1PR3GRM5SRC | |
| SCHEMBL5309259 | 0.78 | MAPT (0.36) | CTSA | |
| SCHEMBL21381538 | 0.77 | AKR1C3 (0.37) | CDK2CTSAS1PR3KDM4EMEN1 | |
| SCHEMBL21381412 | 0.77 | CTSA (0.34) | CDK2CTSAS1PR3HCAR2GRM5 | |
| SCHEMBL2580431 | 0.75 | ALDH1A1 (0.38) | CTSAKDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL1811481 | 0.74 | LMNA (0.57) | CDK2CTSAS1PR3KMT2A | |
| SCHEMBL8224405 | 0.71 | CTSA (0.32) | CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007035153-A1 | NOVEL PROCESS FOR THE PREPARATION OF 6-METHYL-PYRAZIN-2-YLAMINE | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | claimed |
| EP-2563125-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130040933-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | CASH BRANDON (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2007035153-A1 | NOVEL PROCESS FOR THE PREPARATION OF 6-METHYL-PYRAZIN-2-YLAMINE | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035154-A1 | NOVEL N-PYRAZINIL-PHENYLSULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040933-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | CDK2 181/4885CTSA 2624/4885S1PR3 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.